Sarah DiSalvatore, MPH

Sarah DiSalvatore, MPH has extensive experience in the field of clinical operations. Sarah is currently working as the Vice President of Clinical Operations at Ascidian Therapeutics since April 2023. Prior to this, they served as the VP of Clinical Development Operations at AGTC from November 2021 to April 2023. Sarah also worked as the AVP of Clinical Operations at Rocket Pharmaceuticals from March 2021 to November 2021.

Before joining Rocket Pharmaceuticals, Sarah worked at Roche as a Partnership Liaison from October 2018 to March 2021. Prior to that, they worked as a Senior Program Leader at RRD International, LLC/ClearPath from September 2016 to October 2018. Sarah also served as the Vice President of Clinical Operations at NuCana BioMed Ltd from December 2015 to June 2016.

Sarah has held significant positions at Stemline Therapeutics, Inc., serving as the Vice President of Clinical Operations from January 2013 to November 2015. Sarah also worked as a Senior Director at Stemline Therapeutics from July 2012 to December 2013. Prior to Stemline, Sarah was the Senior Director of Clinical Operations at Helsinn Therapeutics from July 2010 to July 2012.

Sarah gained experience at ImClone Systems as an Associate Director from July 2007 to June 2010. Additionally, Sarah served as an Associate Director of Clinical Operations at Alba Therapeutics from February 2006 to July 2007.

Throughout their career, Sarah DiSalvatore has demonstrated their expertise in clinical operations, making their a valuable asset in the field.

Sarah DiSalvatore, MPH has a Master of Public Health (MPH) degree in Epidemiology from New York Medical College. Sarah also holds a Bachelor of Science (BS) degree in Biology from Salisbury University.